What is William Blair’s Estimate for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at William Blair issued their Q1 2025 earnings per share estimates for shares of Tenax Therapeutics in a report released on Wednesday, March 26th. William Blair analyst M. Phipps forecasts that the specialty pharmaceutical company will post earnings of ($0.19) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.87) EPS and FY2026 earnings at ($0.94) EPS.

Several other brokerages also recently commented on TENX. StockNews.com began coverage on Tenax Therapeutics in a research note on Friday, March 21st. They set a “sell” rating on the stock. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Stock Up 5.0 %

Shares of TENX opened at $6.49 on Friday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The company has a market capitalization of $25.73 million, a P/E ratio of -1.22 and a beta of 2.20. The firm has a 50 day moving average of $6.43 and a 200 day moving average of $5.42.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.34.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TENX. Vestal Point Capital LP bought a new stake in Tenax Therapeutics in the 3rd quarter worth approximately $288,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics in the third quarter worth $101,000. Two Sigma Investments LP purchased a new stake in Tenax Therapeutics during the fourth quarter valued at $84,000. Millennium Management LLC bought a new position in Tenax Therapeutics in the fourth quarter valued at about $166,000. Finally, Janus Henderson Group PLC purchased a new position in Tenax Therapeutics in the fourth quarter worth about $1,026,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.